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MaBACKGROUND Large cohort studies provide conﬂicting evidence regarding the potential for oral macrolide antibiotics
to increase the risk of serious cardiac events.
OBJECTIVES This study performed a meta-analysis to examine the link between macrolides and risk of sudden cardiac
death (SCD) or ventricular tachyarrhythmias (VTA), cardiovascular death, and death from any cause.
METHODS We performed a search of published reports by using MEDLINE (January 1, 1966, to April 30, 2015) and
EMBASE (January 1, 1980, to April 30, 2015) with no restrictions. Studies that reported relative risk (RR) estimates with
95% conﬁdence intervals (CIs) for the associations of interest were included.
RESULTS Thirty-three studies involving 20,779,963 participants were identiﬁed. Patients taking macrolides, compared
with thosewho took nomacrolides, experienced an increased risk of developing SCD or VTA (RR: 2.42; 95%CI: 1.61 to 3.63),
SCD (RR: 2.52; 95% CI: 1.91 to 3.31), and cardiovascular death (RR: 1.31; 95% CI: 1.06 to 1.62). No association was found
between macrolides use and all-cause death or any cardiovascular events. The RRs associated with SCD or VTA were
3.40 for azithromycin, 2.16 for clarithromycin, and 3.61 for erythromycin, respectively. RRs for cardiovascular death
were 1.54 for azithromycin and 1.48 for clarithromycin. No association was noted between roxithromycin and adverse
cardiac outcomes. Treatment with macrolides is associated with an absolute risk increase of 118.1 additional SCDs or
VTA, and 38.2 additional cardiovascular deaths per 1 million treatment courses.
CONCLUSIONS Administration of macrolide antibiotics is associated with increased risk for SCD or VTA and
cardiovascular death but not increased all-cause mortality. (J Am Coll Cardiol 2015;66:2173–84)
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ABBR EV I A T I ON S
AND ACRONYMS
CHD = coronary heart disease
CI = conﬁdence interval
CV = cardiovascular
OR = odds ratio
RCT = randomized controlled
trial
RR = relative risk
SCD = sudden cardiac death
VTA = ventricular
tachyarrhythmias
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failed to detect a signiﬁcant relationship
between macrolides and CV risk (5,6). These
inconsistencies among studies could be partly
explained by different types of macrolide
antibiotics, study designs, population char-
acteristics, and different baseline levels of
CV risk and/or disease outcomes. Further-
more, cardiovascular risk may be under-
estimated due to lack of distinction between
former and current macrolide use.
Given this background, the cardiac safety
proﬁles of individual macrolides need to bebetter elucidated to help guide clinical treatment
decisions. Therefore, we conducted a meta-analysis
to examine the link between macrolides and CV risk,
including SCD or ventricular tachyarrhythmias (VTA),
cardiovascular death, death from any cause,
myocardial infarction (MI), stroke, and any cardio-
vascular events.SEE PAGE 2185METHODS
We searched MEDLINE (source, PubMed; January 1,
1966, to April 30, 2015) and EMBASE (January 1, 1980,
to April 30, 2015) using the following text and key
words in combination, both as MeSH terms and
text words: macrolides, azithromycin, erythromycin,
clarithromycin, roxithromycin, cardiac, cardiovascu-
lar, death, mortality, ventricular tachycardia, ven-
tricular arrhythmia, torsades de pointes, sudden
cardiac death, and cardiac arrest. We searched articles
published in any language and scrutinized references
from these studies to identify other relevant studies.
To minimize differences, studies were required:
1) to contain the minimum information necessary to
estimate the relative risk (RR) associated with mac-
rolides and a corresponding measure of uncertainty
(i.e., 95% conﬁdence interval [CI], SE, variance, or
p value); 2) to be cohort studies, case-control studies,
or randomized controlled trials (RCTs) published as
original articles (case reports and prevalence studies
were excluded); and 3) to be independent. In case of
multiple publications/reports on the same population
or subpopulation, we considered the estimates from
the most recent or informative reports.
Three authors (Y-J.C., X-M.C., and X-Y.N.) inde-
pendently extracted the data, which included the ﬁrst
author’s name, publication year, geographical loca-
tion, sex, mean age, study size, study design, sam-
pling framework, study population, number of CV
events, categories of macrolides, covariates adjustedfor in the multivariable analysis, and relative risks
and associated measures of variance for all categories
of macrolides. Primary authors were contacted if the
study did not report data amenable to the creation of
2  2 tables. We used the Newcastle-Ottawa quality
assessment scale (7) to evaluate the quality of cohort
and case-control studies and modiﬁed Jadad score (8)
to evaluate the quality of RCTs. We developed the
evaluation criteria with score ranges from 0 to 9
points for cohort and case-control studies and 0 to 7
points for RCTs, with a higher score indicating higher
study quality.
The primary study endpoint was SCD or VTA, as
deﬁned by International Classiﬁcation of Diseases-
10th revision codes as ventricular tachycardia, tor-
sades de pointes, ventricular ﬁbrillation, ventricular
ﬂutter, sudden cardiac arrest, and SCD. The second-
ary endpoint was CV death, because we hypothesized
that the incidence of cardiac death should be in-
creased if macrolides were pro-arrhythmic. Addi-
tionally, we included an analysis of death from any
cause to examine whether the risk for cardiac death
would be offset by the survival beneﬁt of anti-infec-
tion by macrolides. We also analyzed MI and any CV
events that might precipitate SCD or VTA.
STATISTICAL ANALYSIS. RR was used as a mea-
surement of the association between macrolides and
cardiovascular risk. For case-control studies, the odds
ratio (OR) was used as estimates of the RR because CV
events are sufﬁciently rare (9).
When RR were available, we used the most com-
prehensively adjusted risk estimates reported in the
original manuscript. When the actual RR was not
available, we calculated RRs and 95% CIs by using
Stata version 11.0 software (used for all analyses;
StataCorp LP, College Station, Texas). For studies that
had endpoints with zero events in a treatment arm,
RRs and 95% CI values were calculated using a 0.5 cell
correction (10). We used random rather than ﬁxed
effects models to estimate pooled RRs to account for
heterogeneity, however small, of the risk estimates
and, therefore, to be more conservative. Pooled RRs
were expressed with 95% CIs. We calculated the
I2 (95% CI) statistic to assess heterogeneity across
studies, applying the following interpretation for
I2 <50%, low heterogeneity; 50% to 75%, moderate
heterogeneity; >75%, high heterogeneity (11,12).
Subgroup analyses and metaregression models were
carried out to investigate potential sources of
between-study heterogeneity. We calculated absolute
difference in risk per 1 million treatment courses with
macrolides as: [(RR  1)  I0], where RR indicates
pooled RRs and I0 was the cumulative incidence
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2175of events among patients not taking macrolides.
On the basis of population-based cohort studies, I0
was estimated by weighting the sample size of each
study (4). Small study bias, consistent with publica-
tion bias, was assessed with funnel plot, by using
Begg’s adjusted rank correlation test and Egger’s
regression asymmetry test. Statistical tests were
2-sided and used a signiﬁcance level of p < 0.05.
RESULTS
We initially retrieved 1,559 unique citations, elimi-
nating 831 because they provided no information on
macrolide antibiotics. Of 728 abstracts remaining,
469 were excluded (401 in vitro, functional, or animal
studies; 48 reviews, letters, or editorials; and 20
duplicate reports of the same study population),
leaving 259 articles for detailed evaluation. Subse-
quently, 201 articles were excluded with no relevant
outcomes and another 25 articles were excluded
because they did not provide enough data to estimate
RR (20 were case reports, 2 compared CV risk among
different macrolides; 1 compared CV risk between
macrolides and ﬂuoroquinolones; 1 assessed sex
difference in CV risk associated with macrolides;
and 1 reported only the prevalence of arrhythmia in
macrolides users), leaving 33 studies for ﬁnal inclu-
sion in the meta-analysis (Online Figure 1).
A total of 20,779,963 individuals (59.9% women)
were included in 33 eligible studies. Sixteen studies
were based in Europe, 9 in North America, 2 in East
Asia, 1 in South America, 1 in Asia, and 1 in Africa,
and 3 were multinational. There were 11 population-
based cohorts, 3 case-control studies, and 19 RCTs;
16 studies recruited participants with bacterial in-
fection, and 17 studies were designed to examine
whether macrolides could prevent cardiac events in
patients with coronary heart disease (CHD) or pe-
ripheral artery disease. Study size ranged from 40 to
5,140,594 subjects, with the 6 largest cohort studies
each involving more than 1 million participants.
Nineteen studies evaluated the endpoints of cardio-
vascular risk or all-cause death for azithromycin, 12
clarithromycin, 8 roxithromycin, and 4 erythromycin.
Duration of treatment across the studies ranged from
3 days to 1 year. Data for daily macrolide doses were
reported in 19 RCTs but in none of the observational
studies (Online Table 1). In studies reporting baseline
patient characteristics, mean age, proportion of
women, comorbid condition, and medication use
were not systematically different between patients
taking and not taking macrolides (Online Table 2).
Of the 14 observational studies, the scores of the
Newcastle-Ottawa quality assessment scale qualityassessment ranged from 5 to 9, and 11 studies had
scores of 7 or higher. RCT methodological quality was
generally good, with modiﬁed Jadad score of 4 or
higher in 18 studies (Online Tables 3 to 5).
ASSOCIATION WITH SCD OR VTA. Eleven studies
(3 RCTs, 5 cohort studies, and 3 case-control studies)
with data for 6,639,411 individuals and at least
5,810 events reported risk estimates for SCD or VTA.
Overall, patients taking macrolides experienced a
signiﬁcantly increased risk for developing SCD or
VTA compared to those not on macrolide therapy
(RR: 2.42; 95% CI: 1.60 to 3.63; p <0.001) (Figure 1,
Central Illustration). There was evidence of high het-
erogeneity of RRs across these studies (I2: 85.42%;
95% CI: 75.65% to 91.27%; p < 0.001]) (Figure 1). Risk
estimates changed little after analyses with ﬁxed ef-
fects models or inclusion of studies with more than
10,000 participants, yet substantial heterogeneity
remained. When the analysis was conﬁned to those
studies with propensity-matched cohorts, the overall
combined RR did not materially change, but no evi-
dence of signiﬁcant heterogeneity was observed
among the remaining studies (Table 1). Of note, in a
case-control study by Poluzzi et al., the adjusted risk
estimate for macrolide antibiotics (RR: 7.65; 95% CI:
5.47 to 10.71) was much higher than the pooled risk
estimate. After excluding this single study, there was
no evidence of heterogeneity (I2: 16.36%; 95% CI: 0%
to 57.57%; p ¼ 0.29) and the pooled risk estimate still
reached statistical signiﬁcance (RR: 1.89; 95% CI: 1.58
to 2.26) (Table 1) (13). Neither funnel plots nor Egger
and Begg test results showed evidence of publication
bias (Egger test: p ¼ 0.44; Begg test: p ¼ 0.11) (Online
Figure 2).
To further explore study heterogeneity, we per-
formed stratiﬁed analyses across various key study
characteristics and clinical factors; increased risk of
SCD or VTA associated with macrolides was consis-
tently observed in most of these analyses (Table 2).
Number of events, geographical area, baseline dis-
ease, average age, publication year, or whether risk
proﬁles were adjusted were not signiﬁcant sources of
heterogeneity. Risk estimates were systematically
higher in studies with a higher proportion of females
than males compared with studies where <50% of the
study population were female, but the difference was
not statistically signiﬁcant. Of note, subgroup anal-
ysis showed risk of SCD or VTA was still signiﬁcantly
increased in RCTs for CHD (RR: 2.35; 95% CI: 1.61
to 3.42), with no evidence of signiﬁcant heterogeneity
(I2: 0%; 95% CI: 0% to 89.60%; p ¼ 0.62). Time of
macrolide use appeared to be associated with the re-
sults; the RR for current use was 2.48 versus 1.52 for
FIGURE 1 Relative Risks of Mortality or VTA
.25 .5 1 2 4 8 16 32 64
RR (95% CI)
Source, yr Macrolides No macrolides RR (95% CI) Weight (%)
Ventricular Tachyarrhythmias
or Sudden Cardiac Death
Cardiovascular Death
Muhlestein JB, 2000
Zahn R, 2002
Ray WA, 2004
Straus SM, 2005
Poluzzi E, 2009
Zambon A, 2009
Winkel P, 2011
Ray WA, 2012
Schembri S, 2013
Chou HW, 2014
Rao GA, 2014
Overall, random–effects
1/150 (0.7%)
20/433 (4.6%)
10/2044 (0.5%)
4/9 (44.4%)
39/3024 (1.3%)
17/100 (17.0%)
73/2172 (3.4%)
22/347795 (0.006%)
16/1261 (1.3%)
66/459988 (0.014%)
155/594792 (0.03%)
0/152 (0%)
12/439 (2.7%)
1358/433979 (0.3%)
771/6301 (12.2%)
1626/1298815 (0.1%)
1258/10364 (12.1%)
27/2200 (1.2%)
33/1391180 (0.002%)
9/1713 (0.5%)
127/1102358 (0.011%)
166/979380 (0.02%)
Muhlestein JB, 2000
Sinisalo J, 2002
Stone AF, 2002
Grayston JT, 2005
Andersen SS, 2010
Albert RK, 2011
Winkel P, 2011
Ray WA, 2012
Schembri S, 2013
Svanstrom H, 2013
Chou HW, 2014
Svanstrom H, 2014
Overall, random–effects
5/150 (3.3%)
2/74 (2.7%)
5/111 (4.5%)
65/2004 (3.2%)
138/5265 (2.6%)
1/558 (0.2%)
111/2172 (5.1%)
29/347795 (0.008%)
111/1261 (8.8%)
17/1102419 (0.002%)
49/459988 (0.01%)
50/749285 (0.007%)
4/152 (2.6%)
1/74 (1.4%)
5/107 (4.7%)
75/2008 (3.7%)
2790/169406 (1.6%)
1/559 (0.2%)
78/2200 (3.5%)
41/1391180 (0.003%)
98/1713 (5.7%)
146/7364292 (0.002%)
142/1102358 (0.01%)
235/4355309 (0.005%)
Death from Any Cause
Gupta S, 1997
Gurfinkel E, 1997
Neumann F, 2001
Zahn R, 2002
Cercek B, 2003
O’Connor CM, 2003
Berg HF, 2005
Grayston JT, 2005
Vainas T, 2005
Joensen JB, 2007
Andersen SS, 2010
Albert RK, 2011
Winkel P, 2011
Dogra J, 2012
Ray WA, 2012
Giamarellos EJ, 2013
Keenan JD, 2013
Schembri S, 2013
Svanstrom H, 2013
Khosropour CM, 2014
McEvoy C, 2014
Mortensen EM, 2014
Rao GA, 2014
Overall, random–effects
1/40 (2.5%)
0/102 (0%)
16/519 (3.1%)
8/433 (1.8%)
23/716 (3.2%)
175/3866 (4.5%)
10/238 (4.2%)
143/2004 (7.1%)
20/257 (7.8%)
28/248 (11.3%)
1205/5265 (22.9%)
19/558 (3.4%)
213/2172 (9.8%)
0/32 (0%)
36/347795 (0.01%)
56/302 (18.5%)
51/19229 (0.3%)
320/1261 (25.4%)
63/1102419 (0.006%)
3/162385 (0.002%)
52/411 (12.7%)
3848/38787 (9.9%)
251/594792 (0.04%)
3.04 (0.12, 74.03)
1.70 (0.80, 3.60)
2.01 (1.08, 3.75)
3.70 (0.90, 15.70)
7.65 (5.47, 10.71)
2.13 (1.34, 3.39)
2.61 (1.69, 4.05)
2.71 (1.58, 4.64)
2.41 (1.07, 5.45)
1.40 (1.03, 1.90)
1.56 (1.18, 2.07)
2.42 (1.60, 3.63)
1.43
8.77
9.67
4.94
11.50
10.74
10.92
10.25
8.34
11.66
11.78
100.00
1.27 (0.35, 4.63)
5.00 (0.15, 157.70)
0.80 (0.29, 2.22)
0.87 (0.63, 1.20)
1.59 (1.40, 1.80)
1.00 (0.06, 15.98)
1.45 (1.09, 1.94)
2.88 (1.79, 4.63)
1.54 (1.12, 2.12)
0.93 (0.56, 1.55)
0.94 (0.68, 1.32)
1.32 (0.79, 2.21)
1.31 (1.06, 1.62)
2.31
0.36
3.45
12.43
16.48
0.55
13.19
9.27
12.50
8.67
12.22
8.58
100.00
2.16 (0.20, 23.27)
0.20 (0.01, 4.03)
1.23 (0.75, 2.00)
1.00 (0.40, 2.70)
0.80 (0.46, 1.38)
0.93 (0.76, 1.13)
1.10 (0.42, 2.89)
1.09 (0.86, 1.36)
0.78 (0.45, 1.38)
1.16 (0.66, 2.04)
1.50 (1.37, 1.63)
0.91 (0.49, 1.67)
1.26 (1.03, 1.54)
0.09 (0.00, 2.05)
1.85 (1.25, 2.75)
1.08 (0.77, 1.57)
0.83 (0.61, 1.14)
1.15 (0.95, 1.39)
0.85 (0.65, 1.10)
0.90 (0.15, 5.40)
0.67 (0.54, 0.81)
0.77 (0.73, 0.81)
1.30 (1.01, 1.68)
1.03 (0.86, 1.22)
0.48
0.31
4.43
2.19
4.05
6.38
2.16
6.20
3.98
3.96
6.86
3.67
6.37
0.29
5.09
5.35
5.66
6.43
5.99
0.80
6.36
6.94
6.05
100.00
2/180 (1.1%)
2/100 (2.0%)
13/518 (2.5%)
8/439 (1.8%)
29/723 (4.0%)
188/3856 (4.9%)
9/235 (3.8%)
132/2008 (6.6%)
25/252 (9.9%)
26/257 (10.1%)
25848/169406 (15.3%)
21/559 (3.8%)
171/2200 (7.8%)
1/8 (12.5%)
79/1391180 (0.006%)
51/298 (17.1%)
115/22316 (0.5%)
377/1713 (22.0%)
556/7364292 (0.008%)
2/97663 (0.002%)
154/566 (27.2%)
4819/34903 (13.8%)
317/979380 (0.03%)
Relative risks (RR) of sudden cardiac death (SCD) or ventricular tachyarrhythmia (VTA), cardiovascular death and death from any cause associated with
macrolides were compared to no macrolide use. The size of each square is proportional to the study’s weight (inverse of variance). Dotted line in the forest
plot represents random effects summary risk estimate. CI ¼ conﬁdence interval.
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CENTRAL ILLUSTRATION Macrolides Antibiotics and Cardiovascular Risk
Cheng, Y.-J. et al. J Am Coll Cardiol. 2015; 66(20):2173–84.
Relative risks (RR) of mortality and cardiovascular events. CI ¼ conﬁdence interval; SCD ¼ sudden cardiac death; VTA ¼ ventricular tachyarrhythmia.
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2177former use (p ¼ 0.03). A further stratiﬁed analysis
showed that increased risk of SCD or VTA was
observed in users of azithromycin, clarithromycin,
and erythromycin, but not roxithromycin (Table 2).
In a sensitivity analysis of patients currently taking
penicillin or amoxicillin versus those who took no
antibiotics, there was no association with increased
SCD risk (RR: 0.99; 95% CI: 0.62 to 1.58; p ¼ 0.96).
However, relative to penicillin or amoxicillin, mac-
rolides were associated with an increased risk of SCD
or VTA (RR: 1.69; 95% CI: 1.27 to 2.25; p < 0.001)
(Online Figure 3).
Five studies used SCD as the endpoint of interest,
involving 2,189,416 patients and 2,323 events. Deﬁ-
nitions of SCD differed slightly: 3 studies used World
Health Organization criteria but 2 did not follow
conventional deﬁnitions. Cases were determined
by multiple sources and adjudicated by a blinded
investigator in 4 studies and by death certiﬁcates that
were not validated in 1 study (Online Table 6).
Treatment with macrolides was signiﬁcantly associ-
ated with increased risk of SCD (RR: 2.51; 95% CI: 1.91
to 3.31; p < 0.001]), with no evidence of signiﬁcant
between-study heterogeneity (I2 ¼ 0%; 95% CI: 0%
to 79.2%; p ¼ 0.93) or publication bias (Egger test,
p ¼ 0.81; Begg test, p ¼ 0.56) (Online Figure 4).Patients taking no macrolides experienced an
average of 79.8 (95% CI: 70.7 to 89.5) cases of SCD or
VTAs and 24.1 (95% CI: 16.6 to 32.9) cases of SCDs
per 1 million treatment courses. As compared with no
macrolide use, current macrolide treatment was
associated with an estimated 118.1 (95% CI: 104.6
to 132.4) additional SCD or VTAs and 36.6 (95% CI:
25.2 to 50.0) additional SCDs per 1 million treatment
courses.
ASSOCIATIONWITH CV DEATH. Twelve studies (6 RCTs
and 6 cohort studies) were included for the outcome
of CV death, involving 17,060,440 participants and
4,199 events. Overall, macrolide use was associated
with an increased risk of CV death (RR: 1.31; 95% CI:
1.06 to 1.62; p ¼ 0.01]), with moderate between-study
heterogeneity (I2: 64.8%; 95% CI: 34.84% to 80.99%;
p ¼ 0.001]) (Figure 1, Central Illustration). Risk esti-
mates did not materially change after analyses with
ﬁxed-effect models, inclusion of the studies with
populations >10,000 and with propensity-matched
cohort, or exclusion of the largest study and 1
outlier study, with moderate-to-high heterogeneity
across studies (Table 1) (Egger test, p ¼ 0.94; Begg
test, p ¼ 0.10) (Online Figure 2).
In stratiﬁed analyses, there was no signiﬁcant
heterogeneity by study design, number of events,
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2178geographical area, baseline disease, mean age, pub-
lication year, or proportion of females. However,
stronger associations between macrolides and
CV death were found in studies adjusted for cardio-
vascular risk factors. Additionally, we found evidence
for heterogeneity by time of macrolide use, with the
risk of CV death stronger for current than for former
macrolide use (p ¼ 0.04) (Table 2). Although macro-
lide type was not a signiﬁcant source of heterogene-
ity, azithromycin and clarithromycin but not
roxithromycin were associated with increased risk of
CV death (Table 2).
In the sensitivity analysis, current use of penicillin
or amoxicillin was not associated with an increased
risk of CV death compared with no current antibiotic
use (RR: 1.03; 95% CI: 0.67 to 1.58; p ¼ 0.89). However,
compared with penicillin or amoxicillin, the relative
risk associated with current use of macrolides was 1.24
(95% CI: 1.001 to 1.55; p ¼ 0.049); and, compared with
no use of macrolides, the relative risk associated with
former use ofmacrolides was 0.94 (95% CI: 0.81 to 1.10;
p ¼ 0.46) (Online Figure 5). The average event rate of
cardiovascular death in patients not taking macrolides
was 51.6 (95% CI: 47.5 to 55.8) per 1 million treatment
courses. Using the summary estimates obtained from
all studies combined, we estimated that current use of
macrolides was associated with an absolute risk in-
crease of 38.2 (95% CI: 35.2 to 41.3) cardiac deaths per 1
million treatment courses.
ASSOCIATION WITH DEATH FROM ANY CAUSE. The
endpoint of death from any cause occurred in 39,486
patients among 12,356,873 participants from 23 studies
(15 RCTs, 8 cohort studies, and no case-control
studies). Overall, use of macrolides was not signiﬁ-
cantly associated with all-cause death (RR: 1.03;
95% CI: 0.86 to 1.22; p ¼ 0.77 (Figure 1, Central
Illustration). There was evidence of considerable het-
erogeneity of RRs across these studies (Table 1,
Figure 1). The ﬁndings from the sensitivity analyses
showed that risk estimates changed little based on
different inclusion and exclusion criteria, but consid-
erable heterogeneity was still present (Table 2). These
measures of heterogeneity were likely driven by the
extremely large overall number of participants in this
analysis (>6million). Begg test (p¼0.09) and the Egger
test (p ¼ 0.26) results provided no statistical evidence
for publication bias (Online Figure 2).
In the stratiﬁed analyses, little heterogeneity was
explained by study design, number of events, type of
macrolides, geographical area, baseline disease,
average age, proportion of females studied, time of
macrolide use, publication year, or whether risk pro-
ﬁles were adjusted. Notably, an increased risk of
TABLE 2 Stratiﬁed Analysis and Heterogeneity Analysis of RRs of Mortality or VTA*
Factors Stratiﬁed
SCD or VTA Cardiovascular Death Death From Any Cause
Events Patients RR (95% CI) p Value† Events Patients RR (95% CI) p Value† Events Patients RR (95% CI) p Value†
All studies 5,810 6,639,411 2.42 (1.603.63) 4,199 17,060,440 1.31 (1.061.62) 39,486 12,356,873 1.03 (0.861.22)
Type of studies
Case-control 3,715 1,319,375 4.00 (1.4411.08) 0.02      
Cohort 1,962 5,314,490 1.74 (1.382.20) 3,846 17,050,271 1.58 (1.202.07) 0.17 37,930 12,292,218 1.07 (0.801.45) 0.67
RCT 133 5,546 2.35 (1.613.42) 353 10,169 1.12 (0.831.52) 1,556 64,655 1.03 (0.941.14)
Events, n
S100 5,697 4896288 2.45 (1.454.24) 0.86 4,105 15,319,680 1.32 (1.061.65) 0.25 39,220 12,090,421 1.06 (0.861.30)) 0.56
<100 113 1,743,123 2.34 (1.603.44) 94 1,740,760 1.71 (0.863.39) 266 266,452 0.97 (0.771.21)
Type of macrolide
Azithromycin 2,204 5,784,391 3.40 (1.686.90) 0.84 560 11,380,439 1.54 (1.241.90) 0.31 11,125 12,171,177 0.93 (0.801.08) 0.02
Clarithromycin 2,665 2,811,858 2.16 (1.702.74) 3,540 3,302,883 1.48 (1.321.64) 28,260 183,090 1.28 (1.101.50)
Roxithromycin 32 872 1.70 (0.803.60) 267 1,869,899 1.04 (0.721.51) 101 2,606 1.14 (0.811.61)
Erythromycin 1,843 443,095 3.61 (1.0911.99)      
Location
Europe 2,207 25,754 2.31 (1.763.03) 0.48 3,787 13,753,688 1.56 (1.391.74) 0.48 29,026 8,652,934 1.15 (0.981.35) 0.29
North America 1,745 3,749,472 1.85 (1.412.44) 221 1,744,406 1.44 (0.613.42) 9,876 3,652,991 1.01 (0.781.30)
Asia 193 1,562,346 1.40 (1.031.90) 191 1,562,346 0.94 (0.681.32) 1 40 0.09 (0.012.04)
Baseline disease
Infection 5,677 6,643,865 2.48 (1.504.12) 0.81 920 16,876,717 1.60 (1.072.40) 0.35 10,984 12,159,832 1.04 (0.841.28) 0.97
CHD 133 5,546 2.35 (1.613.42) 3,279 183,723 1.27 (0.951.69) 28,502 197,041 1.02 (0.811.27)
Age
S65 yrs 2,175 24,882 2.42 (1.813.24) 0.87 3,478 187,364 1.32 (1.041.67) 0.32 37,222 262,780 1.07 (0.801.43) 0.49
<65 yrs 3,635 6,624,529 2.36 (1.294.31) 721 16,873,076 1.83 (0.903.72) 2,264 12,094,093 0.99 (0.821.18)
Female proportion
S50% 3,306 4,852,157 2.71 (1.265.86) 0.46 918 16,875,600 1.73 (1.032.93) 0.29 1,967 10,513,269 0.97 (0.771.22) 0.45
<50% 2504 1,597,254 1.90 (1.552.34) 3,281 184,840 1.27 (0.961.67) 37,519 1,843,604 1.06 (0.831.34)
Time periods of macrolides use
Current‡ 5,377 6,643,865 2.48 (1.504.12) 0.03 712 14,320,477 1.74 (1.022.97) 0.04 11,468 12,165,063 0.98 (0.821.16) 0.30
Former§ 1,633 493,070 1.52 (0.892.58) 3.858 11,201,500 1.12 (0.861.45) 28,018 191,810 1.12 (0.921.37)
Adjusted for risk proﬁlesk
Yes 5,752 6,645,263 2.50 (1.554.04) 0.70 4,038 17,054,791 1.55 (1.251.92) 0.04 37,985 12,075,677 1.09 (0.841.43) 0.34
No 58 4,148 2.02 (1.173.48) 161 5,649 0.88 (0.661.19) 1,501 281,196 0.96 (0.811.15)
Publication yr
S2010 694 4,882,839 1.91 (1.442.54) 0.43 4,037 17,055,760 1.54 (1.241.90) 0.06 38,628 12,339,892 1.04 (0.831.31) 0.74
<2010 5,116 1,766,572 2.93 (1.445.95) 162 4,680 0.89 (0.661.20) 858 16,981 0.99 (0.881.13)
*Compared with no macrolide use. †p values test homogeneity between strata. ‡Deﬁned according to days of supply from the day the prescription was ﬁlled. §Deﬁned as some use of a study medication that was not current but had occurred within the previous
365 days. kAdjusted for age, sex, and cardiovascular risk factors.
CHD ¼ coronary heart disease; RCT ¼ randomized controlled trial; other abbreviations are as in Table 1.
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FIGURE 2 Relative Risk of Cardiovascular Events
Source, yr Macrolides No macrolides RR (95% CI) Weight (%)
Myocardial Infarction
Stroke
Any Cardiovascular Events
Gupta S, 1997
Gurfinkel E, 1997
Muhlestein JB, 2000
Neumann F, 2001
Sinisalo J, 2002
Stone AF, 2002
Zahn R, 2002
Cercek B, 2003
O’Connor CM, 2003
Berg HF, 2005
Grayston JT, 2005
Vainas T, 2005
Winkel P, 2011
Giamarellos EJ, 2013
Schembri S, 2013
Mortensen EM, 2014
Overall, random–effects
2/40 (5.0%)
0/102 (0%)
4/150 (2.7%)
20/509 (3.9%)
4/74 (5.4%)
23/111 (20.7%)
8/433 (1.8%)
17/716 (2.4%)
145/3866 (3.8%)
1/238 (0.4%)
136/2004 (6.8%)
19/257 (7.4%)
160/2172 (7.4%)
1/302 (0.3%)
37/1261 (2.9%)
1948/38787 (5.0%)
15/180 (8.3%)
2/100 (2.0%)
6/152 (3.9%)
18/518 (3.5%)
9/74 (12.2%)
31/107 (29.0%)
12/439 (2.7%)
22/723 (3.0%)
153/3856 (4.0%)
3/235 (1.3%)
130/2008 (6.5%)
15/252 (6.0%)
148/2200 (6.7%)
0/298 (0%)
38/1713 (2.2%)
1523/34903 (4.4%)
0.58 (0.14, 2.42)
0.20 (0.01, 4.03)
0.68 (0.19, 2.35)
1.18 (0.76, 1.83)
0.40 (0.12, 1.30)
0.90 (0.58, 1.40)
0.70 (0.30, 1.70)
0.78 (0.42, 1.47)
0.95 (0.76, 1.18)
0.33 (0.01, 3.49)
1.05 (0.83, 1.32)
1.24 (0.65, 2.39)
1.10 (0.88,  1.36)
2.96 (0.12, 72.38)
1.32 (0.85, 2.07)
1.11 (1.03, 1.20)
1.08 (1.01, 1.15)
0.19
0.04
0.25
2.03
0.28
2.02
0.52
1.00
8.09
0.05
7.27
0.92
8.26
0.04
1.98
67.08
100.00
Muhlestein JB, 2000
Sinisalo J, 2002
Zahn R, 2002
Grayston JT, 2005
Giamarellos, 2013
Overall, random–effects
1/150 (0.7%)
2/74 (2.7%)
4/433 (0.9%)
45/2004 (2.2%)
0/302 (0%)
3/152 (2.0%)
2/74 (2.7%)
0/439 (0%)
40/2008 (2.0%)
1/298 (0.3%)
0.34 (0.04, 3.21)
1.00 (0.14, 6.91)
9.12 (0.49, 168.96)
1.13 (0.74, 1.72)
0.33 (0.01, 8.04)
1.10 (0.74, 1.64)
3.30
4.18
1.86
89.24
1.42
100.00
Gupta S, 1997
Muhlestein JB, 2000
Leowattana W, 2001
Sinisalo J, 2002
Zahn R, 2002
Cercek B, 2003
O’Connor CM, 2003
Berg HF, 2005
Albert RK, 2011
Winkel P, 2011
Dogra J, 2012
Schembri S, 2013
Mortensen EM, 2014
3/40 (7.5%)
28/150 (18.7%)
17/43 (39.5%)
11/74 (14.9%)
81/433 (18.7%)
152/716 (21.2%)
551/3866 (14.3%)
20/238 (8.4%)
49/558 (8.8%)
351/2172 (16.2%)
2/32 (6.3%)
196/1261 (15.5%)
16873/38787 (43.5%)
26/180 (14.4%)
35/152 (23.0%)
16/41 (39.0%)
19/74 (25.7%)
62/439 (14.1%)
148/723 (20.5%)
579/3856 (15.0%)
19/235 (8.1%)
56/559 (10.0%)
303/2200 (13.8%)
3/8 (37.5%)
243/1713 (14.2%)
14895/34903 (42.7%)
0.50 (0.16, 1.57)
0.81 (0.52, 1.26)
1.01 (0.60, 1.73)
0.54 (0.25, 1.14)
1.40 (1.00, 2.00)
1.03 (0.82, 1.29)
0.95 (0.85, 1.06)
1.04 (0.55, 1.98)
0.88 (0.61, 1.26)
1.20 (1.02, 1.39)
0.13 (0.03, 0.57)
1.53 (1.23, 1.92)
1.02 (0.99, 1.06)
1.05 (0.94, 1.17)
0.95
4.93
3.73
2.02
6.93
10.95
16.34
2.72
6.53
14.24
0.58
11.11
18.98
100.00
.25 .5 1 2 4 8 16 32 64
RR (95% CI)
Overall, random–effects
Relative risks (RR) of myocardial infarction, stroke, and any cardiovascular events associated with macrolides were compared to no macrolide use. The size of
each square is proportional to the study’s weight (inverse of variance). Dotted line in the forest plot represents random-effects summary risk estimate.
CI ¼ conﬁdence interval.
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2180all-cause death was observed in users of clari-
thromycin (p<0.001), but not in users of azithromycin
and roxithromycin (Table 2, Online Figure 6).
We performed further analysis of the endpoint of
noncardiovascular death from 4 studies, involving734 events in 10,211,175 participants. Compared
with no macrolide use, macrolide treatment was
not associated with an increased risk of non-
cardiovascular death (RR: 0.94; 95% CI: 0.78
to 1.14; p ¼ 0.53), with no evidence of between-study
J A C C V O L . 6 6 , N O . 2 0 , 2 0 1 5 Cheng et al.
N O V E M B E R 1 7 / 2 4 , 2 0 1 5 : 2 1 7 3 – 8 4 Macrolides and Cardiovascular Risk
2181heterogeneity (I2: 0%; 95% CI: 0% to 84.69%; p ¼ 0.51)
(Online Figure 7).
The average all-cause death rate in patients not
taking macrolides was 90.0 (95% CI: 84.2 to 96.1) per
1 million treatment courses. Macrolide treatment was
not associated with absolute increased risk of death
from any cause: 2.7 (95% CI: 12.6 to 19.8) cases per
1 million treatment courses.
ASSOCIATION WITH MI, STROKE, AND ANY CV
EVENTS. For MI, 16 studies were included, reporting
4,560 events among 98,780 participants. The overall
RR of MI in patients taking macrolides, compared with
those who took no antibiotics, was 1.08 (p ¼ 0.02)
(Central Illustration) with no signiﬁcant between-study
heterogeneity (p ¼ 0.69) (Figure 2). The funnel plot
showed evidence of publication bias (Egger, p ¼ 0.34;
Begg, p <0.001) (Online Figure 2). When we removed
the largest study by Mortensen and colleagues (6), no
signiﬁcant association between macrolides and MI
remained (RR: 1.02; 95% CI: 0.91 to 1.14; p ¼ 0.73), but
publication bias among the remaining studies was
no longer signiﬁcant (Egger test, p ¼ 0.11; Begg test,
p ¼ 0.09). The study by Mortensen et al. (6) demon-
strated a signiﬁcant association between macrolides
and MI (RR: 1.11; 95% CI: 1.03 to 1.20). This study was
similar in quality and methodology to the remaining
studies, except that the participants it enrolled were
older patients hospitalized with pneumonia.
Of 5 studies analyzed, there were 98 strokes among
5,934 participants. Evidence synthesis for stroke did
not show a statistically signiﬁcant association with
macrolides (p ¼ 0.63), with no signiﬁcant between-
study heterogeneity (p ¼ 0.46) (Figure 2).
Thirteen studies involving 93,503 participants
were analyzed reporting a total of 34,738 total CV
events. Overall, macrolide use was not signiﬁcantly
associated with an increased risk of any CV events
(p ¼ 0.42), with moderate heterogeneity between
studies (p < 0.001) (Figure 2). Similar results were
obtained using ﬁxed-effect models (RR: 1.03; 95% CI:
0.996 to 1.06; p ¼ 0.09). There was no statistical ev-
idence of publication bias (Egger test, p ¼ 0.34; Begg
test, p ¼ 0.10) (Online Figure 2).
DISCUSSION
The present meta-analysis, involving 20,819,622
individuals from 33 studies, found signiﬁcantly
increased risk of SCD or VTA, cardiovascular death,
and MI in users of macrolides. This association with
increased CV risk seemed to be present with current
use of macrolides and disappeared for former use.
In stratiﬁed analysis, azithromycin, clarithromycin,
and erythromycin were associated with increasedrisk of SCD or VTA and azithromycin and clari-
thromycin with increased risk of CV death, but only
clarithromycin was associated with increased risk of
all-cause mortality. In terms of absolute risk, use of
macrolides would account for an estimated 118.1
SCD or VTAs, 36.6 SCDs, and 38.2 cardiac deaths per
1 million courses.
Interpretation of the clinical importance of this
ﬁnding is delicate. The estimates for additional SCDs
and cardiac deaths per 1 million treatment courses are
remarkably close, suggesting that most VTA observed
in the macrolide groups might not result in fatal
outcomes. The absolute risks for SCD and cardiac
death are small, so this ﬁnding should probably have
limited effect on prescribing practice in individual
patients. However, given that macrolides are 1 of
the more commonly used antibiotic groups in many
countries and that millions of patients are prescribed
these drugs annually, the total number of excess SCD
or VTAs and cardiac deaths may not be negligible.
Results of the study raise the question, why would
macrolides be associated with increased risk for car-
diac death but not all-cause mortality? Several plau-
sible explanations have been suggested. First, Sligl
et al. (14) reported a reduction in any cause death in
a subgroup of patients with severe community-
acquired pneumonia, indicating an increased risk of
CV death might be partly offset by the survival beneﬁt
of anti-infection by macrolides. Second, in addition to
antimicrobial properties, macrolides have been
demonstrated to have immunomodulatory effects in
the treatment of diffuse panbronchiolitis, cystic
ﬁbrosis, bronchiectasis, and asthma and signiﬁcantly
reduce noncardiovascular death (15). However,
among the small number of studies included in our
analysis, risk of non-CV death was not signiﬁcantly
decreased in the general population, suggesting these
hypotheses need further conﬁrmation.
Another factor may confound the association be-
tween macrolides and CV risk. Patients taking mac-
rolides might be sicker and have higher CV risk than
patients not taking antibiotics; therefore, the
increased risk observed in our study may be related to
the acute infection itself. Nevertheless, in the anal-
ysis of studies with propensity-matched cohorts that
provide more robust control for confounders than
adjustment, the results were similar to the main
ﬁndings. Furthermore, the risk of CV death was
similar in patients with no or former macrolide use,
indicating that baseline differences between the
groups did not likely inﬂuence the results signiﬁ-
cantly. The fact that no signiﬁcant differences were
observed for all-cause death should further lessen
concerns about systematic differences in health
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2182status at baseline as an explanation for the observed
association with increased CV risk. Additionally,
compared with amoxicillin or penicillin, macrolide
use was associated with signiﬁcantly increased risk,
indicating that the increased risk was attributable to
the prescribed treatment rather than infection effect.
Understanding the mechanisms that underlie the
association between macrolides and CV risk will help
frame appropriate therapeutic decisions. Our results
suggest that association may be largely mediated by
an acute toxic mechanism, supported by the higher
risk observed in current users of macrolides and
that ventricular arrhythmias occurred mainly during
short-term therapy. For many drugs with proar-
rhythmic effects, an elevated serum concentration is
a key determinant of increased risk (16), which may
be an important reason why increased cardiovascular
risk did not persist after macrolide therapy ended.
Blockage of the Ikr encoded by human ether-a-go-
go-related gene (HERG), prolongation of the QT in-
terval, and, thus, increased risk of VTA are thought to
be the underlying mechanisms for acute cardiac
toxicity with macrolides (17). Therefore, macrolides
might increase the risk of severe cardiac arrhythmias
in patients with baseline risk factors for QT prolonga-
tion, such as hypokalemia, hypomagnesia, and con-
current use of class IA and III antiarrhythmic agents
(18). Furthermore, there might be a concomitant,
synergistic effect of acute infection on the arrhythmic
risk intrinsically associated with macrolide antibiotics
(19). Our study indicated that risk of SCD or VTA was
increased in patients with bacterial infection, as well
as in those with CHD intrinsically burdened by high
arrhythmic risk (20). In particular, many basic studies
demonstrated that proinﬂammatory cytokines may
promote arrhythmias directly by affecting cardiac
electrophysiology (21). Guo et al. (19) previously re-
ported an almost linear increase in HERG block and
action potential prolongation by erythromycin over a
temperature range of 37C to 42C. Clarithromycin and
erythromycin also are extensively metabolized by cy-
tochrome P-450 (CYP3A) isozymes, and the serum
concentration could be elevated by concomitant use of
CYP3A-inhibiting drugs, which may further increase
risk of macrolide-associated SCD (3). Of note, our re-
sults suggest that macrolide use seems to be associ-
ated with a mild increased risk of MI. Macrolides may
activate mast cells residing within atherosclerotic le-
sions, leading to release of vasoactive mediators into
the bloodstream, and thus coronary artery vasospasm
and platelet activation, resulting in more vulnerable
plaques that, over time, might contribute to increased
risk of MI or SCD by plaque rupture (22). This hypoth-
esis is inconsistent with the ﬁndings in other studiesthat azithromycin might inhibit activation of mono-
cytes and macrophages and the inﬂammatory process
in vivo, indicating further experimental studies are
needed to elucidate the speciﬁc pathogenic mecha-
nisms (23,24).
Notably, we observed an increase in risk of SCD
or VTA with azithromycin, clarithromycin, and
erythromycin but not with roxithromycin. Available
mechanistic data comparing individual macrolides
suggest that clarithromycin and erythromycin have
higher potency of Ikr inhibition compared with roxi-
thromycin, and thus higher potential for QT prolon-
gation and proarrhythmic properties (25). Although
azithromycin has been considered the safest of the
macrolides, as it neither undergoes CYP3A meta-
bolism nor inhibits CYP3A to any clinically meaning-
ful degree, and only shows the weakest blockade of
Ikr in vitro (26), our results suggest that azithromycin
might increase SCD risk similar to clarithromycin and
erythromycin. Therefore, the in vitro data about azi-
thromycin’s pharmacodynamic property might not
truly reﬂect how it works in vivo. In 2013, the U.S.
Food and Drug Administration and pharmaceutical
manufacturer issued public safety notiﬁcations
warning of SCD risk with azithromycin. However, a
safety warning of greater CV risk might also apply to
erythromycin and, especially, to clarithromycin.
Additionally, the absence of an association between
roxithromycin and CV risk in our study shows roxi-
thromycin’s relative cardiac safety.
STUDY LIMITATIONS. Strengths of this meta-analysis
include the strict inclusion criteria, the large number
of patients analyzed, the diversity of the study pop-
ulation, and the fact that all subgroup analyses were
pre-speciﬁed. The absence of important publication
bias supports the robustness of the study ﬁndings.
Still, there were some study limitations. First, a large
amount of heterogeneity was observed in the results
of the various studies. Although differences in time
periods of macrolide use seems to explain this at least
partially, heterogeneity still exists in the outcome of
any-cause death. However, similar risk estimates
were consistently observed in all stratiﬁed analyses,
indicating heterogeneity might not inﬂuence the re-
sults signiﬁcantly. Limited data on macrolide doses in
observational studies make it difﬁcult to determine
whether differences in doses would be the source of
heterogeneity.
Second, because original studies did not report data
on electrocardiographic (ECG) monitoring or QT in-
tervals, we could not exclude the possibility of ascer-
tainment bias of VTA, because patients placed on
antiarrhythmic agents, with a possible proarrhythmic
potential, might be more likely to receive ECG
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Meta-analysis
suggests that patients taking macrolide antibiotics for treatment
of established or presumed bacterial infections experienced
increased rates of ventricular tachyarrhythmias, sudden cardiac
death, and cardiovascular death. Users of clarithromycin faced an
increased risk of death from any cause, but there was no asso-
ciation between roxithromycin and adverse cardiac outcomes.
TRANSLATIONAL OUTLOOK: Large randomized trials are
needed to conﬁrm or refute these ﬁndings prospectively and
identify individual patient features that predict adverse
outcomes.
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2183monitoring, which would bias VTA detection. How-
ever, VTA with hemodynamic instability would be
easy to degenerate to SCD if untreated. Therefore,
episodes of these types of VTA are less likely to be
misdiagnosed or undetected. Also, the retrospective,
death certiﬁcate-based method of surveillance of SCD
for 1 study might result in overestimation of SCD
incidence (27). However, sensitivity analysis of risk for
SCD yielded results similar to themain ﬁnding, with no
evidence of signiﬁcant heterogeneity, indicating the
method of case determination may not inﬂuence the
results signiﬁcantly.
Third, lack of individual participant data may pre-
clude exploring in depth the interaction of CYP3 in-
hibitors and macrolides and other individual variables
that may also inﬂuence outcomes. For example, fe-
male sex is an independent risk factor for torsades de
pointes caused by cardiac drugs due to an intrinsic
longer QTc interval compared to males and, indeed,
we observed a trend towards higher risk in studies
with predominantly female patients (28,29); however,
limited data on the sex-stratiﬁed analysis of patients
in the original studies preclude further sex analysis.
Additionally, although a previous report suggests that
drug-induced torsade de pointes might be a late phe-
nomenon (29), we could not calculate the mean time
interval between treatment with macrolides and car-
diac event of interest based on the data available.
Fourth, like all meta-analyses, our study has the
limitation of being a retrospective analysis; thus,
further large RCTs are warranted to conﬁrm these
ﬁndings.
CONCLUSIONS
Results of this meta-analysis suggest that macrolides
may be associated with signiﬁcant increased riskfor SCD or VTA and cardiovascular death but not
all-cause mortality. The observed association with
increased CV risk seemed to be largely attributed to
current use of macrolides. This calls for large well-
designed RCTs to further elucidate the CV safety of
macrolides. Lack of signiﬁcant difference in all-cause
death between users of macrolides and no macrolides
provide reassurance to clinicians that administration
of macrolide antibiotics might be generally safe.
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